

MSCA on ECTRIMS 2022 Amsterdam

9 Chairs, 20 Presentations, 22 Posters, 7 ePosters

Wednesday 26 October

PRESENTATIONS & CHAIRS

Educational Session 6 (MAGNIMS): MRI and the diagnosis of MS - where we are and what the future is (Room 4)

Speaker: Frederik Barkhof, NL
MS mimics: red and green flags

09:20 - 09:35

Hot Topic 3: Novel body fluid biomarkers (Room 4)

Speaker: Charlotte Teunissen, NL
Emerging blood biomarkers

10:15 - 10:25

Welcome to ECTRIMS 2022 (Room 1)

Chair: Bernard Uitdehaag, NL

11:30

Speaker: Bernard Uitdehaag, NL

11:30 - 12:00

Scientific Session 1: Personalised treatment (Room 1)

Speaker: Zoé van Kempen, NL
Personalised dosing of monoclonal antibodies in MS

14:50 - 15:05

Scientific Session 2: A network disease (Room 2)

Speaker: Menno M. Schoonheim, NL
The network collapse and clinical progression

14:50 - 15:05

Speaker: Tommy A. A. Broeders, NL

Reduced network dynamics in cognitively impaired MS patients
might be explained by more energetically costly state
transitions

15:19 - 15:26

Scientific Session 4: Novel modelling approaches (Room 4)

Speaker: Samantha Noteboom, NL
Multi-centre assessment of artificially generated MRI for cortical
and juxtacortical multiple sclerosis lesion detection

15:19 - 15:26

POSTERS

P033 Temprano - the amsterdam early relapsing-remitting multiple sclerosis cohort: an introduction on the cognitive and psychological functioning of the cohort

Speaker: Maureen van Dam, NL

P171 Weight during childhood and adolescence is associated with multiple sclerosis risk and disease course in a cohort patients of the same age

Speaker: Floor C. Loonstra, NL

P172 Dietary factors in childhood are associated with multiple sclerosis risk and age of onset

Speaker: Floor C. Loonstra, NL

P207 The effect of natalizumab, fingolimod and first-line treatment on brain atrophy in patients with multiple sclerosis

Speaker: Samantha Noteboom, NL

P208 Feasibility of detecting atrophy relevant for disability and cognition on 3D-FLAIR

Speaker: Samantha Noteboom, NL

P220 Cross-sectional robustness of 6 freely available software packages for brain volume measurements in multiple sclerosis

Speaker: David Rudolf van Nederpelt, NL

P249 A novel signature of lipoxin A4 and prostaglandin E2 in plasma associated with disease severity in patients with relapsing remitting and secondary progressive multiple sclerosis

Speaker: Jelle. Y Broos, NL

P302 Discontinuation of first-line disease-modifying therapy in multiple sclerosis

Speaker: Eline M.E. Coerver, NL

P390 The effect of aerobic training on neuro-specific blood-based biomarkers in people with multiple sclerosis - a secondary analysis of a randomized clinical trial

Speaker: Arianne Gravesteijn, NL

P1194 Robustness of the thalamus against network disruption is related to cognitive status in MS patients

Poster Presenter: Julia Rosa Jelgerhuis, NL

Thursday 27 October

PRESENTATIONS & CHAIRS

Hot Topic 5: Escalating and de-escalating DMTs (Room 1)

Chair: Joep Killestein, NL

10:00

Speaker: Eva Strijbis, NL

Long-term stable MS on platform therapies

10:25 - 10:35

Hot Topic 6: Inclusion of optic nerve lesions in McDonald criteria (Room 2)

Speaker: Frederik Barkhof, NL

Rationale and detection by MRI

10:05 - 10:15

Hot Topic 7: Lifestyle interventions (Room 4)

Speaker: Brigit de Jong, NL

Diet

10:15 - 10:25

Scientific Session 7: Advanced mobility assessment (Room 3)

Speaker: Vincent de Groot, NL

3D gait analysis

11:50 - 12:05

Scientific Session 8: Immune cell trafficking into the CNS (Room 4)

Chair: Jack van Horssen, NL

11:30

Scientific Session 12: The earliest events in MS (Room 4)

Chair: Jeroen Geurts, NL

15:00

Young Scientific Investigators' Session 3: Long-term outcomes and safety (Room 7)

Chair: Bob van Oosten, NL

15:00

Educational Session 12: Cognitive impairment in MS - an update (Room 8)

Speaker: Menno M. Schoonheim, NL

Underlying Mechanisms

15:20 - 15:35

POSTERS

P504 Validation of the MS-IADL-Q to measure cognitive functioning in daily life

Speaker: Maureen van Dam, NL

P537 Co-culture of iPSC-derived microglia and iPSC-derived astrocytes: modeling multiple sclerosis white and grey matter lesion environments

Speaker: Thecla A. van Wageningen, NL

P551 Chemerin correlates with MS progression parameters and affects intracellular metabolism in human microglia and macrophages

Speaker: Merel Rijnsburger, NL

P555 Understanding B cell migration after personalized dosing of ocrelizumab in multiple sclerosis patients

Speaker: Carla Rodriguez-Mogeda, NL

P587 Regional altered diffusion in lesional and normal-appearing cortex is linked to cognitive impairment in multiple sclerosis

Speaker: Eva A. Kijnen, NL

P588 Cortical lesions in functional networks are related to cortical atrophy, but only in normal-appearing grey matter

Speaker: Eva A. Kijnen, NL

P601 The association between age and inflammatory disease activity on MRI in relapse onset multiple sclerosis

Speaker: Eline M.E. Coerver, NL

P634 Validation of a semi-automated method to quantify lesion volume changes in multiple sclerosis on 2D proton densityweighted images using subtraction imaging

Speaker: Rozemarijn M Mattiesing, NL

P671 Can we detect radiological disease activity in multiple sclerosis using digital biomarkers?

Speaker: Pam Christina Gea Molenaar, NL

P679 Unraveling the power spectrum in multiple sclerosis phenotypes: an explorative magnetoencephalography study

Speaker: Lodewijk Reinier Johannes De Ruiter, NL

P680 Magnetoencephalography as a potential predictor of clinical progression in patients with multiple sclerosis: a longitudinal study

Speaker: Lodewijk Reinier Johannes De Ruiter, NL

P739 Safety of shorter ocrelizumab infusion confirmed over multiple administrations: results of the ENSEMBLE PLUS substudy

Speaker: Joep Killestein, NL

Friday 28 October

PRESENTATIONS & CHAIRS

Educational Session 20: Approaches to alternative treatment algorithms (Room 8)

Chair: Joep Killestein, NL

10:00

Chair: Eva Strijbis, NL

10:00

Speaker: Bob van Oosten, NL

Biosimilars and off-label therapies

10:05 - 10:20

Speaker: Eva Strijbis, NL

When to stop disease modifying therapy

10:20 - 10:35

Speaker: Joep Killestein, NL

Personalised and extended dosing of monoclonal antibodies

10:35 - 10:50

Scientific Session 16: Cognition (Room 1)

Speaker: Hanneke Hulst, NL

Prevention versus treatment

12:20 - 12:35

Speaker: Ilse M. Nauta, NL

Cognitive rehabilitation and mindfulness reduce cognitive complaints in multiple sclerosis (REMIND-MS): a randomized controlled trial

12:49 - 12:56

Scientific Session 17: Blood based biomarkers: when to implement? (Room 2)

Speaker: Mark H.J. Wessels, NL

Serum glial fibrillary acidic protein as a biomarker of disease-progression in a natalizumab-treated cohort of patients with relapsing-remitting multiple sclerosis

12:42 - 12:49

Hot Topic 9: Pharmacovigilance (Room 4)

Speaker: Joep Killestein, NL

How to manage CNS complications

12:25 - 12:35

Hot Topic 10: Emerging role of lipids in MS (Room 5)

Chair: Gijs Kooij, NL

12:00

Plenary Session 2: Awards,ECTRIMS Honorary Members, Confavreux Lecture and ECTRIMS 2022 Highlights (Room 1)

Chair: Bernard Uitdehaag, NL

17:00

Speaker: Elga de Vries, NL

Scientific highlights

17:45 - 17:55

ePOSTERS

EP0803 Floor Loonstra

Blood platelet RNA as biomarker for the detection of

EP0858 Monique Schokker

Resilience and perceived stress in recently diagnosed people with MS: Relations with quality of life and psychosocial outcomes.

EP0872 Sam Hof

The evolution of internuclear ophthalmoparesis in multiple sclerosis: a one year follow-up study

EP0890 Antonio Luchicchi

Early signs of myelin degeneration in the diffusely abnormal white matter in MS

EP0914 J. Konings

Epigenetic profiling of blood in multiple sclerosis: a closer look at lipid mediator machinery gene regulation

EP0971 David van Nederpelt

QSM in MS shows large regional susceptibility differences but is constant over time

EP1142 Arianne Gravesteijn

Energy expenditure, energy cost and relative aerobic load of walking in people with multiple sclerosis